Drug Profile
Axatilimab - Syndax Pharmaceuticals
Alternative Names: Anti-CSF-1R monoclonal antibody - Syndax Pharmaceuticals; Axatilamab; INCA-34176; SNDX-6352; UCB 6352Latest Information Update: 25 Mar 2024
Price :
$50
*
At a glance
- Originator UCB
- Developer AstraZeneca; Incyte Corporation; Syndax Pharmaceuticals
- Class Antifibrotics; Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Macrophage colony stimulating factor receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preregistration Graft-versus-host disease
- Phase II Cholangiocarcinoma; Hodgkin's disease; Idiopathic pulmonary fibrosis; SARS-CoV-2 acute respiratory disease; Triple negative breast cancer
- No development reported Cancer; Solid tumours
Most Recent Events
- 20 Mar 2024 Incyte Corporation plans a phase-I/II trial for Solid tumours (Combination therapy, Second-line therapy or greater, Metastatic disease) in USA (IV) (NCT06320405)
- 29 Feb 2024 FDA assigns PDUFA action date of (28/08/2024) for Axatilimab for Graft-verses-host-disease
- 27 Feb 2024 Axatilimab receives priority review status for Graft-verses-host-review in USA